Thymol

Synopsis

Thymol: A Comprehensive Reference Article

1. Identity and Chemical Characterization

1.1 Chemical Names and Structural Identity

Thymol, also known as 2-isopropyl-5-methylphenol (IPMP), has the molecular formula C₁₀H₁₄O and is a monoterpenoid, phenol derivative of p-cymene, isomeric with carvacrol. Its CAS registry number is 89-83-8. It occurs naturally in oil of thyme and is extracted from Thymus vulgaris (common thyme), ajwain, and various other plants, presenting as a white crystalline substance with a pleasant aromatic odor. Thymol is only slightly soluble in water at neutral pH, but due to deprotonation of the phenol group, it is highly soluble in alcohols, other organic solvents, and strongly alkaline aqueous solutions.

Thymol (2-isopropyl-5-methylphenol) belongs to the phenolic monoterpenes and mostly occurs in thyme species. Thymol is a derivative of cymene and is known for its range of pharmacological properties, especially its broad use in medicine as an anti-infective, antioxidant, anti-inflammatory agent, and for hepatoprotective activities.

1.2 Natural Sources

Thymol is a natural volatile monoterpenoid phenol that is the main active ingredient of oil extracted from species Thymus vulgaris L., commonly known as thyme, and other plants such as Ocimum gratissimum L., Origanum L., Carum copticum L., different species of the genus Satureja L., Oliveria decumbens Vent, and many others.

Among many constituents, thymol is abundantly found in certain plants such as Thymus vulgaris, Ocimum gratissimum, Thymus ciliatus, Satureja thymbra, Thymus zygis, Trachyspermum ammi, Carum copticum, Satureja intermedia, Thymbra capitata, Lippia multiflora, Thymus pectinatus, Zataria multiflora, Satureja hortensis, Centipeda minima, and Nigella sativa seeds.

Oil of thyme, the essential oil of common thyme, contains 20–54% thymol. Thyme essential oil is defined as a product of the steam distillation of fresh flowering aerial parts of one or a mixture of both species (T. vulgaris or T. zygis) with 37–55% thymol and 0.5–5.5% carvacrol concentrations.

A number of these plants constitute a rich source of thymol; this product is often associated with its isomer, carvacrol. This natural phenol occurs in many essential oils including Thymus and Origanum spp. and the Monarda genus (bee balm, horsemint, etc.), giving a strong herb scent.

1.3 Common Forms and Preparations

Traditional extraction techniques such as steam distillation remain in use, whereas emerging methods — including ultrasound-assisted extraction and supercritical fluid extraction — have markedly improved the efficiency, yield, and purity of thymol extraction. From the perspective of synthesis, thymol can be produced chemically via alkylation of m-cresol, or it can be generated biologically through the methylerythritol phosphate (MEP) pathway.

Commercially, thymol is available in several forms:

Crystalline isolate — pure thymol crystals obtained by fractional distillation and crystallization from crude essential oils, used in pharmaceutical manufacturing.
Thyme essential oil — the steam-distilled whole essential oil of Thymus vulgaris or Thymus zygis, standardized under the European Pharmacopoeia.
Herbal preparations — standardized dry extracts used in finished medicinal products (e.g., Bronchipret, Bronchicum), tinctures, teas, and infusions.
Oral antiseptic formulations — thymol is an active ingredient in various commercially produced mouthwashes, such as Listerine.
Encapsulated and nanoformulations — novel therapeutic formulations, such as nanocapsules containing thymol, can be beneficial in medicinal practice and create opportunities for extensive use.

A thyme herb obtained from Thymus vulgaris L. and Thymus zygis L. is the most well-known herbal substance in the pharmaceutical industry. Today, only standardized preparations of thyme herb and essential oil that meet the requirements of national pharmacopeias or European Pharmacopoeia X (Ph. Eur. X) are used for the production of medicines.

According to the Ph. Eur. X definition, thyme herb is described as whole leaves and flowers separated from the dried stems of T. vulgaris or T. zygis or their mixture with 12 mL/kg of minimum essential oil and minimum thymol and carvacrol contents of 40%.

2. Traditional and Historical Use

2.1 Ancient Mediterranean Civilizations

Thyme (Thymus vulgaris) has been used medicinally since antiquity, with records from ancient Egypt documenting its use as a preservative and embalming agent, and ancient Greek and Roman physicians including Dioscorides and Pliny the Elder prescribing thyme-based preparations for respiratory ailments, digestive complaints, and wound infection.

Ancient Egyptians used common thyme for embalming. The ancient Greeks used it in their baths and burnt it as incense in their temples, believing it was a source of courage. The name 'thymus' is derived from the Greek word 'thumos', meaning 'courage' or 'to fumigate', reflecting its historical use in ancient cultures as a symbol of bravery and for purification rituals.

The Greeks, Romans, and Egyptians used thyme as a preservative, odorant, and flavoring agent in foods. It is a small subshrub abundantly used as a traditional medicine in the western Mediterranean region, and its leaves are often used as herbal medicinal products and food additives.

2.2 Medieval European Herbalism

In medieval European herbalism, thyme was a cornerstone of monastic pharmacopeias, used as an expectorant, antispasmodic, and antimicrobial remedy, with thymol isolation first achieved by the German pharmacist Caspar Neumann in 1719 and structural characterization completed in the 19th century.

Thymol has been historically used as an antibiotic and antiseptic, especially in traditional medicine. Both thymol and thyme essential oil have long been used in traditional medicine as expectorant, anti-inflammatory, antiviral, antibacterial, and antiseptic agents, mainly in the treatment of the upper respiratory system.

2.3 Ayurvedic Medicine

Traditional Ayurvedic medicine employs ajwain (Trachyspermum ammi), another high-thymol plant, extensively for digestive disorders, flatulence, and respiratory infections, with preparations including decoctions, powders, and steam inhalation.

2.4 Traditional Chinese and Other Asian Systems

Thymol has been used traditionally in India as well as China for various biological activities. In fact, thymol and its main natural source are employed for their positive potential in diverse therapeutic functions, namely antioxidant, antimicrobial, anti-inflammatory, local anaesthetic, antiseptic, antibacterial, anthelmintic, spermicidal, depigmenting, analgesic, antidiarrhoeal, abortifacient, antihypertensive, insecticidal, anticholinesterase, and antifungal activities.

2.5 Thymol in Official Monographs

According to the German Commission E and ESCOP monographs, thyme herb is indicated for bronchitis and catarrh of the upper airways. The ESCOP monograph further specifies internal use for catarrh of the upper airways, bronchitis, and supportive treatment for whooping cough; and locally as a mouthwash for inflammation of the oral mucosa and for bad breath. The German Commission E monograph covers internal use for bronchitis, relief of whooping cough symptoms, and catarrh of the upper respiratory tract; empirical medicine traditions also employ thyme for loss of appetite, bloating, flatulence, as an antiseptic mouthwash, and as a bath additive or liniment for dermatoses and rheumatic diseases.

3. Key Constituents and Active Compounds

Thymol itself is the principal bioactive monoterpenoid under discussion here, but it is commonly found alongside related phytochemicals in its botanical sources:

Thymol (2-isopropyl-5-methylphenol) — the primary bioactive phenol and the focus of this article.
Carvacrol — thymol is often associated with its isomer, carvacrol, which shares many pharmacological properties.
Other phenolic terpenoids — β-caryophyllene, γ-terpinene, α-thujene, linalool, gallic acid, naringin, and rutin are other phytochemicals of thyme species.
Flavonoids — flavonoids in thyme include luteolin-7-O-glucoside, a glycoside known for its antioxidant and anti-inflammatory properties, as well as apigenin, quercetin, and kaempferol.
Phenolic acids — phenolic acids such as rosmarinic acid, known for its antioxidant, anti-inflammatory, and antimicrobial activities, along with caffeic acid and chlorogenic acid, are also present in thyme.

4. Established Mechanisms of Action

4.1 Antimicrobial and Antifungal Mechanisms

The antimicrobial activity of thymol is among the most thoroughly characterized in preclinical research. Thymol disrupts the permeability and fluidity of bacterial cell membranes, resulting in the loss of membrane integrity and impairment of energy metabolism. Mechanistic studies suggest its actions may involve disrupting cell membranes, interfering with energy metabolism, and inhibiting DNA replication, repair, and transcription, underscoring its potential as a natural antimicrobial agent.

Cell membrane depolarization, decreased intracellular ATP concentrations, and lower intracellular pH (pHi) are observed after treatment with thymol, which indicates broken cell membranes and disrupted intracellular homeostasis.

Against fungal organisms specifically, numerous studies have revealed that thymol predominantly exerts its antifungal activity by disrupting the structure of the cell membrane, affecting membrane ion channels, altering the DNA structure, and interfering with the material and energy metabolism of the pathogen. Previous studies have shown that thymol limits ergosterol biosynthesis and disrupts membrane integrity, showing potent fungicidal efficacy against clinical Candida isolates. Thymol induced a significant increase in malondialdehyde (MDA) concentration and a remarkable decrease in ergosterol content; taken together, thymol showed potential antifungal activity due to cell membrane damage originating from lipid peroxidation and disturbance of ergosterol biosynthesis.

The chemical configuration of thymol gives it hydrophobic properties and allows it to deposit on the lipophilic structures of microorganisms such as the plasma membrane; this deposition leads to increased permeability with a consequent loss of electrolytes essential to cell survival. Other action mechanisms may be involved, such as the inhibition of spore germination, fungal proliferation, and cell respiration.

4.2 Anti-Inflammatory Mechanisms

Thymol inhibits the dissociation of the IκB protein and NF-κB dimer and the activation of the mitogen-activated protein kinase (MAPK) signaling pathway to relieve inflammation.

In vitro, thymol dose-dependently inhibited the expression of TNF-α, IL-1β, inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) in LPS-stimulated RAW264.7 cells. Moreover, thymol dose-dependently suppressed LPS-induced reactive oxygen species (ROS) production.

Regarding COX enzyme inhibition specifically, one study reports that thymol is more active against the COX-1 enzyme, where the half-maximal inhibitory effect (IC₅₀) was determined to be 0.2 µM; in contrast, a number of synthesized thymol-pyrazole hybrids exerted more potent anti-inflammatory effects, where thymol (IC₅₀ = 0.043–0.068 µM) strongly inhibited the COX-2 enzyme.

4.3 Antioxidant Mechanisms

Thymol possesses antibacterial, antifungal, anti-inflammatory, antioxidant, anti-mutagenic, larvicidal, analgesic, anti-microbial, acaricidal, anticonvulsant, antiepileptogenic, wound healing, anti-hemolytic, antiphlogistic, antileishmanial, and radioprotective properties. Its free radical scavenging activity is attributed to the phenolic hydroxyl group, which donates hydrogen atoms to neutralize reactive oxygen species.

4.4 Effects on Smooth Muscle

In dose-response studies, IC₅₀ values for thymol were calculated as 5.26 mM for the ileum and 5.35 mM for the uterus (ex vivo in rat tissue), demonstrating the efficacy of thymol in reducing ileal and uterine smooth muscle contractions, thus supporting the use of thyme in traditional medicine in the treatment of digestive disorders and painful menstrual cramps.

5. Scientific Evidence by Area of Use

5.1 Respiratory System — Bronchitis and Upper Respiratory Tract Infections

The strongest clinical evidence for thymol-containing preparations relates to upper respiratory tract conditions, particularly as part of combination herbal products. Essential oil compounds such as found in thyme extract are established for the therapy of chronic and acute bronchitis.

Bronchipret TP (thyme-primrose) clinical trial: In a double-blind, placebo-controlled, multicenter Phase IV study, 361 outpatients with acute bronchitis — with ≥10 coughing fits during the day and a Bronchitis Severity Score (BSS) ≥5 — were randomly assigned to 11-day treatment (1 tablet three times daily) with either thyme-primrose combination (Bronchipret TP FCT; N=183) or placebo (N=178).

Comparative matched-pair study: The study was designed as a matched-pair comparison of 7,783 patients; clinical outcomes of bronchitis and adverse reactions were documented. Data were evaluated by comparing treatment success of the test medication and 3 control groups using ordinal regression. The results suggest that clinical effectiveness of Bronchipret® was not less than with synthetic drugs, with a tendency for better results with Bronchipret®, particularly in the treatment of adults.

Recent randomized clinical trial: In a three-arm, open-label, randomized clinical trial, patients with acute bronchitis were assigned to groups receiving Ivy extract EA 575 (Prospan® Cough Drops), Ivy/Thyme extract combination (Bronchipret® Drops), or Thyme/Primrose extract combination (Bronchicum® Drops), with 325 adult patients evaluated. Non-inferiority of Ivy extract was statistically significant against both thyme-containing comparators (both p<0.0001), while superiority of Ivy extract over Ivy/Thyme extract was also statistically significant (p<0.0001).

Mechanistic evidence supporting respiratory use: A herbal medicinal product containing a combination of thyme and ivy extracts (Bronchipret®) exerts anti-inflammatory and mucus-normalizing effects in LPS-induced bronchoalveolitis in vivo, potentially via inhibition of 5-LO and PDE4 activities; these effects may contribute to the observed clinical efficacy in acute bronchitis.

Evidence strength: No human randomized controlled trials with defined sample sizes, primary endpoints, or effect size metrics for thymol as an isolated compound were identified in the searched literature, representing a significant gap between robust preclinical data and clinical validation. The compound's role in thyme-based herbal preparations (e.g., Bronchipret) is supported by some clinical data, but these studies evaluate the whole extract rather than isolated thymol, making attribution to thymol specifically difficult. Overall, clinical evidence for thyme-containing combination preparations in upper respiratory conditions is moderate, while evidence for isolated thymol is currently limited to pharmacokinetic and preclinical studies.

5.2 Oral Health — Dental Plaque, Gingivitis, and Oral Microbial Control

Thymol is an active ingredient in various commercially produced mouthwashes, such as Listerine. Listerine® has a unique blend of essential oils composed of eucalyptol, thymol, methyl salicylate, and menthol; the four essential oils, found in natural plant sources, are responsible for its antimicrobial action.

Published evidence from short- and long-term clinical trials support the benefit of adding an essential oil-containing mouthwash (Listerine®) to the daily oral regimen to maintain personal oral hygiene. Essential oils in Listerine® have been found to have equally effective anti-gingivitis properties as chlorhexidine after 6 months of use.

Evidence is accumulating that Listerine® is effective in improving oral health, but the absence of systematic toxicological studies means that an accurate safety assessment cannot be made.

Evidence strength: For the multi-ingredient essential oil mouthwash, clinical evidence is moderate-to-strong based on multiple randomized controlled trials. However, as thymol is one of four active components in these formulations, its individual contribution cannot be isolated from available trial data.

5.3 Antimicrobial and Antifungal Activity

The antimicrobial properties of thymol are among its most extensively documented activities, though the bulk of evidence remains in vitro or in animal models. A comparative assessment integrating experimental antimicrobial data and computational analyses indicated that thymol consistently exhibited superior antimicrobial performance among the tested compounds, with lower MIC values (0.10–0.20 mg/mL) and stable predicted binding interactions with key microbial targets, including FtsZ (Kd = 3.2 × 10⁻¹⁰ M) and sterol 14-α-demethylase (Kd = 6.1 × 10⁻⁶ M).

Regarding antifungal activity against Candida species specifically, studies have demonstrated that thyme extract containing more than 70% thymol had no toxic impact on normal HEK-293 cells even at very high concentrations, and thymol showed negligible toxicity against human erythrocytes (100 µg/ml caused only ~2% hemolysis).

Novel studies have demonstrated antibiofilm, antifungal, antileishmanial, antiviral, and anticancer properties of thymol and thyme essential oil, though the majority of these findings remain preclinical.

Evidence strength: Strong preclinical (in vitro and in vivo animal) evidence for broad-spectrum antimicrobial and antifungal activity. No large-scale human clinical trials exist for isolated thymol as a systemic antimicrobial agent. Clinical use is concentrated in topical/oral antiseptic applications.

5.4 Anti-Inflammatory Activity

A systematic review and meta-analysis examined thymol's anti-inflammatory and wound-healing properties. The review focused on in vitro and in vivo investigations, searching PubMed, Web of Science, and Scopus; PRISMA was followed for data extraction, and RoB 2 and SYRCLE tools were utilized to assess risk of bias for in vitro and animal studies. Thirty-six and 15 articles were included in the qualitative analysis and meta-analysis, respectively. Studies showed high risk of bias related to sampling, allocation procedures, randomization, and blinding. Even so, for in vitro studies, a significant result was observed for IL-2.

An animal study evaluating thymol's effect in rat colitis showed: thymol was dissolved in 0.2% tween 80 in saline and administered orally at doses of 10, 30, and 100 mg/kg per day. Treatment with thymol reduced mucosal and histological damages compared to the acetic acid group. Thymol was found to reduce acetic acid-induced inflammatory response through inhibition of the NF-κB signaling pathway in rat colon tissue.

Evidence strength: Moderate preclinical (in vitro and animal) evidence for anti-inflammatory activity through multiple pathways. No dedicated human clinical trials for isolated thymol as an anti-inflammatory agent currently exist.

5.5 Antitumor and Anticancer Activity

A systematic review published in PMC examined antitumor effects of carvacrol and thymol: a total of 1,170 records were identified, with 77 meeting the established criteria. The studies were published between 2003 and 2021, with 69 being in vitro and 10 in vivo; 43 used carvacrol, 19 thymol, and 15 studies tested both monoterpenes. It was attested that carvacrol and thymol induced apoptosis, cytotoxicity, cell cycle arrest, antimetastatic activity, and also displayed different antiproliferative effects and inhibition of signaling pathways (MAPKs and PI3K/AKT/mTOR).

Carvacrol and thymol exhibited antitumor and antiproliferative activity through several signaling pathways; in vitro, carvacrol appears to be more potent than thymol. However, further in vivo studies with robust methodology are required to define a standard and safe dose, determine their toxic or side effects, and clarify exact mechanisms of action.

Evidence strength: Preliminary — predominantly in vitro evidence. No human clinical trials have been conducted for thymol as an anticancer agent. This area remains in early-stage investigation.

5.6 Neuroprotection

Preclinical animal research has investigated thymol in models of Parkinson's disease. Male Wistar rats were injected with rotenone at a dose of 2.5 mg/kg body weight for 4 weeks to induce Parkinson's disease, and thymol was co-administered for 4 weeks at a dose of 50 mg/kg body weight, 30 minutes prior to rotenone injection. Thymol treatment in rotenone-challenged rats appears to significantly attenuate dopaminergic neuronal loss, oxidative stress, and inflammation. The study showed protective effects of thymol mediated by preservation of endogenous antioxidant defense networks and attenuation of inflammatory mediators including cytokines and enzymes.

Neuroinflammatory mechanisms have been investigated in vitro: in LPS stimulation, thymol (100 µM) treatment markedly reduced IL-1β, IL-6, and TNF-α as well as the expression of inflammatory genes (Il1b, Il6, Tnfa, Cox2, and Nos2). After thymol administration, the phosphorylation levels of IκB and NF-κB (p65) significantly decreased.

Evidence strength: Preclinical only. All neuroprotective evidence is from animal models or cell culture. No human clinical trials have been conducted.

5.7 Gastrointestinal Health

Thymol, a natural monoterpene phenol mostly found in thyme, exhibits multiple biological functions as a potential adjuvant for inflammatory bowel disease (IBD). The exact etiology of IBD remains unclear, but several risk factors such as pathogen infection, stress, diet, age, and genetics are involved in its occurrence and aggravation. Immune system malfunction with over-production of inflammatory cytokines and associated oxidative stress are the hallmarks of IBD. Dietary intervention and medical treatment suppressing abnormal inflammation and oxidative stress are recommended as potential therapies.

Evidence strength: Preclinical. Most evidence is from in vitro and animal studies. No direct human trials on isolated thymol for gastrointestinal conditions have been reported in authoritative literature reviewed.

5.8 Pulmonary Protection

In a preclinical study examining pulmonary fibrosis: treatment groups receiving thymol at 50 mg/kg and 100 mg/kg reduced fibrotic markers (α-SMA and fibronectin), inflammatory mediators (TNF-α, IL-1β, IL-6, and NF-κB), and oxidative stress biomarkers (MDA, GSH, and SOD) relative to the bleomycin group. Thymol effectively prevented bleomycin-induced pulmonary fibrosis by exerting significant anti-oxidant and anti-inflammatory effects. The novel finding that thymol upregulated lung miR-29a expression while decreasing TGF-β and PI3K/Akt signaling is worthy of further investigation as a possible molecular mechanism for thymol's anti-fibrotic actions.

Evidence strength: Preclinical (animal model). Human evidence is absent.

6. Pharmacokinetics and Metabolism in Humans

A dedicated human pharmacokinetic study examined thymol absorption and metabolism after oral dosing. To determine the systemic availability and pharmacokinetics of thymol after oral application to humans, a clinical trial was carried out in 12 healthy volunteers. Each subject received a single dose of a Bronchipret TP tablet, equivalent to 1.08 mg thymol. No free thymol could be detected in plasma or urine; however, the metabolites thymol sulfate and thymol glucuronide were found in urine and identified by LC-MS/MS.

Thymol sulfate, but not thymol glucuronide, was detectable in plasma. Peak plasma concentrations were 93.1 ± 24.5 ng/mL and were reached after 2.0 ± 0.8 hours. The mean terminal elimination half-life was 10.2 hours. Thymol sulfate was detectable up to 41 hours after administration. Urinary excretion could be followed over 24 hours, and the amount of both thymol sulfate and glucuronide excreted in 24-hour urine was 16.2% ± 4.5% of the dose.

At the metabolic level more broadly, thymol undergoes predominant biotransformation via sulfation, and glucuronidation additionally occurs as a metabolic route at higher doses, producing key metabolites such as thymol sulfate, thymol glucuronide, and thymol thymohydroquinone sulfate. These metabolites are mainly excreted via the kidneys. Within 6 hours post-administration, the major metabolites become detectable in urine, with the excretion profile reaching its peak within 24 hours. The combined amount of thymol sulfate and glucuronide in urine accounts for about 16.2% of the administered dose, accompanied by a renal clearance rate of approximately 0.271 L/h.

7. Dosage Forms and Reported Dosages

The following dosages are reported in identified sources and reflect what has been studied or recommended in specific contexts. They should not be interpreted as universal therapeutic recommendations.

Thyme herb infusion (Commission E): 1–2 g drug for tea infusions per cup, with a total daily dose of 3–8 g drug for tea infusions.
Bronchipret TP (thyme-primrose extract tablet): In the Phase IV clinical trial, the dosing was 1 tablet three times daily for 11 days. Each tablet is equivalent to 1.08 mg thymol.
Animal anti-inflammatory studies: Thymol dissolved in 0.2% tween 80 in saline was administered orally at doses of 10, 30, and 100 mg/kg per day.
Animal pulmonary fibrosis study: Thymol doses of 50 mg/kg and 100 mg/kg were tested.
Animal Parkinson's disease model: Rotenone was administered at 2.5 mg/kg for 4 weeks to induce Parkinson's disease, and thymol was co-administered at 50 mg/kg body weight.
Mouthwash (oral antiseptic): Listerine® employs a blend of eucalyptol, thymol, methyl salicylate, and menthol at concentrations that are commercially proprietary, used as a rinse formulation.
Food additive regulatory limits (FDA/EPA): Thymol is added directly to food items such as ice cream and ices at up to 44 ppm, alcoholic and non-alcoholic beverages at 6 ppm each, candy at up to 78 ppm, baked goods at 23 ppm, chewing gum at up to 100 ppm, and gelatins/puddings at 20 ppm.

Data on pharmacological dosing, therapeutic window, and long-term safety of thymol in humans remain insufficient.

8. Body Systems and Health Areas

The scientific literature reveals the pharmacological properties of thymol and its multiple therapeutic actions against various cardiovascular, neurological, rheumatological, gastrointestinal, metabolic, and malignant diseases at both biochemical and molecular levels.

Respiratory system: Expectorant, antispasmodic, and antiseptic activity; clinically studied in bronchitis via combination herbal preparations.
Oral cavity / stomatognathic system: Antimicrobial and anti-plaque properties; a component of clinically validated antiseptic mouthwashes.
Gastrointestinal system: Antispasmodic effects on intestinal smooth muscle demonstrated ex vivo; anti-inflammatory effects studied in animal colitis models.
Immune / inflammatory system: NF-κB, MAPK, COX, and iNOS inhibition demonstrated preclinically.
Nervous system: Neuroprotective effects against dopaminergic neurodegeneration and neuroinflammation in animal and in vitro models.
Integumentary system: Wound healing and cicatrizing properties noted in preclinical research.
Oncological: In vitro and limited in vivo apoptotic and antiproliferative effects; no human data.
Metabolic system: Antidiabetic activity studied in animal models via α-glucosidase inhibition and oxidative stress reduction; no human trials available.

9. Safety Considerations and Interactions

9.1 Regulatory Classification

Thymol is a constituent of oil of thyme, a naturally occurring mixture of compounds in the plant Thymus vulgaris. Thymol has long been a regular part of the human diet and is listed as an approved food additive by the FDA (21 CFR 172.515). Thymol has a long history of safe use as a direct food additive. Additionally, the source plant (thyme), from which thymol is extracted, is acknowledged by FDA as generally recognized as safe (GRAS) (21 CFR 182.10 and 182.20).

Thymol has been classified as "Generally Recognized as Safe" (GRAS) by the FDA, and the U.S. EPA has assigned it a relatively low-risk profile for certain usage.

9.2 Toxicology — Non-Clinical Data

In conducting its hazard assessment for thymol, the EPA relied on data from the open scientific literature, including a combined repeated-dose oral toxicity study with the reproduction/developmental toxicity screening test, genotoxicity studies, and a 6-month inhalation study. No adverse effects were seen at the highest dose tested of 200 mg/kg/day.

In a reproductive safety assessment, no adverse effects were seen up to a dose of 1,875 mg/kg, the highest dose tested. In terms of mutagenicity, the active ingredient was determined to be non-mutagenic, and no adverse effects were identified relative to either developmental toxicity or reproductive toxicity.

An open literature study on the genetic toxicology potential of thymol concluded that thymol is not mutagenic via the micronucleus assay and the mouse lymphoma assay with and without the S9 mitochondrial fraction.

According to the European Chemicals Agency (ECHA), thymol has not shown chronic side effects or teratogenicity in previous studies, and can be considered a safe compound.

9.3 Potential Adverse Effects

Reported side effects of thyme-based preparations include gastrointestinal disorders and, rarely, allergic reactions to thymol. Known contraindications include hypersensitivity to thyme or other Lamiaceae; pregnancy and lactation in the absence of data are also listed as precautionary contraindications.

Eye irritation data from rabbit studies showed that instillation of thymol into the eyes caused corneal opacity which persisted to the final observation at day 28; conjunctival irritation persisted to day 14. Thymol is also corrosive to the skin of rabbits at high concentrations. These findings are relevant primarily to high-concentration occupational exposure rather than to dietary or supplement-level use.

9.4 Drug Interactions

No well-characterized drug interaction studies for isolated thymol in humans exist; theoretical interactions include potentiation of anticoagulant effects (given phenolic compounds' known platelet-aggregation modulation), and potential interference with CYP450 enzyme-metabolized drugs given thymol's hepatic metabolism via glucuronidation and sulfation pathways.

9.5 Bioavailability Limitations

Carvacrol and its isomeric compound thymol are plant-based extracts that possess several biological activities; however, their efficacy is compromised by their poor bioavailability. This is a recognized limitation in translating strong in vitro and animal data to human therapeutic contexts, and has driven interest in novel delivery systems including nanoencapsulation.

Given thymol's lipophilicity and moderate oral bioavailability, clinically relevant applications are more feasible through topical and localized delivery systems.